Sugi Predict

Sugi Predict / Compounds / SCHEMBL877569

SCHEMBL877569

SCHEMBL877569

[CH2]c1cc(OC)cc[n+]1[O-]

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL2 P10415 1/20 0.40
▸ CA1 P00915 3/20 0.35
▸ CA2 P00918 3/20 0.35
▸ CA7 P43166 3/20 0.35
▸ CA9 Q16790 3/20 0.35
▸ CA12 O43570 2/20 0.35
▸ CA14 Q9ULX7 2/20 0.35
▸ ALDH1A1 P00352 5/20 0.35
▸ ACHE P22303 4/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP2A6 P11509 1/20 0.34
▸ CRHBP P24387 1/20 0.34
▸ CRHR2 Q13324 1/20 0.34
▸ KEAP1 Q14145 1/20 0.34
▸ NFE2L2 Q16236 1/20 0.34
▸ CYP3A4 P08684 2/20 0.33
▸ BCHE P06276 1/20 0.33
▸ CCR1 P32246 1/20 0.33
▸ CCR5 P51681 1/20 0.33
▸ CCR8 P51685 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5944757 0.77 BCL2 (0.41) BCL2CA1CA2CA7CA9
SCHEMBL1999459 0.77 BCL2 (0.41) BCL2CA1CA2CA7CA9
SCHEMBL3786646 0.75 BCL2 (0.40) BCL2CA1CA2CA7CA9
SCHEMBL6709391 0.75 BCL2 (0.40) BCL2CA1CA2CA7CA9
SCHEMBL10701753 0.75 BCL2 (0.40) BCL2CA1CA2CA7CA9
SCHEMBL26986441 0.75 BCL2 (0.40) BCL2CA1CA2CA7CA9
SCHEMBL10752466 0.72 BCL2 (0.38) BCL2CA1CA2CA7CA9
SCHEMBL5961894 0.71 BCL2 (0.37) BCL2CA1CA2CA7CA9
SCHEMBL21056503 0.71 KDM4E (0.37) BCL2CA1CA2CA7CA9
SCHEMBL6840996 0.69 BCL2 (0.36) BCL2CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9714560-B2 Protected scale inhibitors and methods relating thereto HALLIBURTON ENERGY SERVICES, INC. (US) 2017-07-25 — — US claimed
WO-2023056089-A1 IMMUNOLOGICAL ADJUVANT FORMULATIONS COMPRISING TLR4 AGONIST E6020 EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-04-06 — — WO disclosed
EP-3934757-B1 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) 2023-02-22 — — EP disclosed
US-20220220134-A1 PHOSPHOHISTIDINE MIMETICS AND ANTIBODIES TO SAME THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2022-07-14 — — US disclosed
US-20220152078-A1 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) 2022-05-19 — — US disclosed
US-11149052-B2 2′3′-cyclic dinucleotides INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) 2021-10-19 — — US disclosed
EP-3774831-A1 2'3'-CYCLIC DINUCLEOTIDES Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. (CZ) 2021-02-17 — — EP disclosed
EP-3774832-A1 3'3'-CYCLIC DINUCLEOTIDES Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. (CZ) 2021-02-17 — — EP disclosed
US-10874740-B2 5-ALA derivatives and use thereof UNIVERSITE DE GENEVE (CH) 2020-12-29 — — US disclosed
CN-111954675-A 3'3' -Cyclic dinucleotides 捷克共和国有机化学与生物化学研究所 2020-11-17 — — CN disclosed
US-7115738-B2 Hydroxyproline/phosphono oligonucleotide analogues, methods of synthesis and methods of use ACTIVE MOTIF (US) 2006-10-03 — — US disclosed
US-6962906-B2 Oligonucleotide analogues, methods of synthesis and methods of use ACTIVE MOTIF (US) 2005-11-08 — — US disclosed
EP-1263773-A4 OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF USE ACTIVE MOTIF (US) 2005-08-31 — — EP disclosed
EP-1481085-A2 OLIGONUCLEOTIDE ANALOGUES AND METHODS OF USE FOR MODULATING GENE EXPRESSION Active Motif (US) 2004-12-01 — — EP disclosed
US-20040014644-A1 Oligonucleotide analogues and methods of use for modulating gene expression ACTIVE MOTIF. 2004-01-22 — — US disclosed
WO-2003068798-A2 OLIGONUCLEOTIDE ANALOGUES AND METHODS OF USE FOR MODULATING GENE EXPRESSION ACTIVE MOTIF (US) 2003-08-21 — — WO disclosed
US-20030059789-A1 Oligonucleotide analogues, methods of synthesis and methods of use ACTIVE MOTIF 2003-03-27 — — US disclosed
EP-1263773-A1 OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF USE Active Motif (US) 2002-12-11 — — EP disclosed
US-20020155989-A1 Oligonucleotide analogues, methods of synthesis and methods of use ACTIVE MOTIF 2002-10-24 — — US disclosed
WO-2001068673-A1 OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF USE ACTIVE MOTIF (US) 2001-09-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11149052-B2 2′3′-cyclic dinucleotides STING1, MAVS, CGAS BCL2 3898/4885CA1 4869/4885CA2 4476/4885
US-20020155989-A1 Oligonucleotide analogues, methods of synthesis and methods of use HIRA, PHAX, SSU72 BCL2 2192/4885CA1 320/4885CA2 896/4885
US-20220152078-A1 2'3'-CYCLIC DINUCLEOTIDES AND PRODRUGS THEREOF STING1, CGAS, NT5C2 BCL2 3222/4885CA1 4468/4885CA2 1455/4885
US-10874740-B2 5-ALA derivatives and use thereof ALAD, ANXA5, AAAS BCL2 3133/4885CA1 2803/4885CA2 2713/4885
US-20040014644-A1 Oligonucleotide analogues and methods of use for modulating gene expression CRYAA, SRRT, HIRA BCL2 1331/4885CA1 402/4885CA2 1386/4885
US-20220220134-A1 PHOSPHOHISTIDINE MIMETICS AND ANTIBODIES TO SAME PHPT1, CD4, CD81 BCL2 4867/4885CA1 1000/4885CA2 2841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.